IMMUNE THROMBOCYTOPENIA A MODERN VIEW OF DIAGNOSIS AND TREATMENT: LITERATURE REVIEW

Authors

  • KAYUMOV Abdurahmon Abdumavlyanovich
  • IBRAGIMOVA Gulchexra Mansurovna
  • ACHILOVA Ozoda Umarkulovna

Keywords:

immune thrombocytopenia, antibodies to platelets, diagnosis of thrombocytopenia, rituximab, intravenous immunoglobulins

Abstract

Primary immune thrombocytopenia (ITP) is a rare (orphan) disease. Hemorrhages are the main clinical symptom. ITP presents with a tendency to bleed, bruise easily (purpura) or seep blood from capillaries into the skin and mucous membranes (petechiae). In modern literature, the results of studies conducted in patients and recommendations are given. The modern arsenal of medicines is replenished annually with new molecules, marked by good tolerance and high safety. One of the current recommendations is the use of IVIG and rituximab, which can quickly stop life-threatening bleeding and delay or avoid splenectomy. The article provides an overview of modern criteria for the diagnosis, classification and treatment of ITP, and also describes the effectiveness of the most commonly recommended drugs.

References

Петров В.Ю., Плахута Т.Г., Сосков Г.И. Вакцино индуцированная острая тромбоцитопеническая пурпура у детей. Педиатрия. 2006; 6: 8–12.

Петров В.Ю., Сосков Г.И., Плахута Т.Г., Агеенкова Э.В. Современные представления о патофизиологии и терапии идиопатической тромбоцитопенической пурпуры. Педиатрия. 2009; 88 (4): 125–134.

Маннанов, Ж., Мусурманов, Ф., & Абдуллажонова, Ш. (2022). Защитные средства- важный фактор при оказании неотложной помощи у больных с флегмонами челюстно-лицевой области при covid-19. Дни молодых учёных, 1(1), 64–66. извлечено от https://inlibrary.uz/index.php/young-scientists/article/view/15058

Beardsley DS. ITP in the 21st century. Hematology (the Education Program of the American Society of Hematology). Sem. Hematol. 2006: 402–407.

Abrahamson P.E., Hall S.A., Feudjo-Tepie M. et al. The incidence of idiopathic thrombocytopenic purpura (ITP) among adults: a population-based study and literature review. Eur J Haematol 2009;83:83–9

Aoki T., Harada Y., Matsubara E. et al. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. J Clin Pharm Ther 2012 Dec;37(6):729–32.

Arnold D.M., Dentali F., Crowther M.A. et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146(1):25–33.

Arnold D.M., Heddle N.M., Carruthers J. et al. A pilot randomized trial of adjuvant rituximab or placebo for non-splenectomized patients with immune thrombocytopenia. Blood 2012 Feb 9;119(6):1356–62.

Maksudov, D., Musurmanov, F., & Nodirhonov, S. (2021). Effectiveness of the complex treatment of odontogenic phlegmon of the maxillofacial region in patients. Збірник наукових праць SCIENTIA. вилучено із https://ojs.ukrlogos.in.ua/index.php/scientia/article/view/10529

Maksudov Dilshod D., Musurmanov Fazliddin I. et al. "Development of a Comprehensive Programme for the Comprehensive Treatment of Patients with Maxillofacial Phlegmon with Viral Hepatitis B." JournalNX, vol. 7, no. 02, 2021, pp. 191-198

Bizzoni L., Mazzucconi M., Gentile M. et al. Idiopathic thrombocytopenic purpura (ITP) in the eldery: clinical course in 178 patients. Eur J Haematol 2006;76(3):210–6.

Boccia R., Kuter D.J., Rummel M.J. et al. The effects of romiplostim or standard of care (SOC) on splenectomy and treatment failure of patients who had immune thrombocytopenia (ITP) for less than or equal to one year. Blood 2010;116(21):3702.

Bussel J.B., Kuter D.J., Pullarkat V. et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161–71.

Bussel J., Rodeghiero F., Lyons R.M. et al. Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim: report of 9 cases. Blood 2011;118(21):3281.

Chen J., Herceg-Harjacek L., Groopman J., Grabarek J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995;86:4054–62.

Ziyadullaev, S., Elmamatov, O., Raximov, N., & Raufov, F. (2020). Cytogenetic and immunological alterations of recurrent bladder cancer. European Journal of Molecular & Clinical Medicine, 7(2), 1877-1883.

Published

2023-10-28